Gilead (GILD) Q2 2025: HIV Base Business Up 4% as Yes2Go Launch Drives Prevention Market Expansion
Gilead’s Q2 marked a pivotal inflection with the launch of Yes2Go, the first twice-yearly HIV prevention injection, and robust commercial execution across HIV, oncology, and liver disease. Base business growth and a disciplined cost structure enabled a guidance raise, while early Yes2Go momentum signals a step-change in HIV prevention market opportunity. Investors should watch for access expansion and international uptake as the next key catalysts.
Summary
- Yes2Go Launch Sets New HIV Prevention Standard: Early adoption and payer wins point to rapid market expansion.
- Base Business Outpaces COVID Decline: HIV, oncology, and liver franchises offset anticipated Veclury headwinds.
- Guidance Raised on Execution: Upgraded revenue and EPS outlook reflects confidence in core growth drivers.
Performance Analysis
Gilead’s Q2 2025 delivered a clear signal of operational and strategic momentum, with base business sales (excluding COVID antiviral Veclury) rising 4% year over year to $6.9 billion. This growth was propelled by strong HIV franchise performance, particularly Biktarvy, single-tablet HIV regimen, and Discovy, HIV prevention pill, which posted 9% and 35% year-over-year gains respectively. Oncology and liver disease also contributed, while Veclury sales fell sharply, as expected, reflecting waning COVID hospitalizations.
HIV remains the company’s economic engine, with $5.1 billion in Q2 sales, up 7% year over year, and now supported by the high-profile launch of Yes2Go, Lenacapavir’s twice-yearly injectable for HIV prevention. Commercial execution was evident in rapid market access wins and exceptional launch readiness, with unaided provider awareness at 72% pre-launch—more than double industry norms. Oncology growth was led by Trodelvy, antibody-drug conjugate for breast cancer, which advanced in both U.S. and international markets. Liver disease saw mixed trends, with new launches offsetting HCV pressure.
- Discovy Growth Outpaces Market: 35% year-over-year sales surge reflects both market expansion and rising share, with U.S. PrEP users now exceeding half a million.
- Oncology Pipeline Execution: Back-to-back positive phase three Trodelvy results support a move into first-line metastatic breast cancer.
- Cost and Margin Discipline: Gross margin improved 1 percentage point to 87%, supported by mix and SG&A discipline.
Gilead’s upgraded guidance and robust clinical pipeline underscore a transition from COVID-reliant revenue to a diversified, innovation-led growth model.
Executive Commentary
"This quarter had special significance, of course, with the FDA approval of Lenincapivir, or Yes2Go, for twice-yearly HIV prevention. This is truly a milestone moment in the history of HIV, with the launch of a groundbreaking innovation that could bend the arc of the epidemic."
Daniel O’Day, Chairman and Chief Executive Officer
"Sequentially, sales in our base business were up 10% driven by growth in HIV, oncology, and liver disease. Including Veclurie, total product sales of $7.1 billion were up 2% year over year. While Veclurie’s share of US hospitalized patients treated for COVID-19 remains well over 60%, the number of patients impacted by the pandemic continues to decline."
Joanna Mercier, Chief Commercial Officer
Strategic Positioning
1. HIV Franchise Reinvention with Yes2Go
Yes2Go’s approval and rapid launch represent a step-function change for Gilead’s HIV prevention business, positioning the company as the leader in long-acting PrEP solutions. Early wins in payer access and high prescriber engagement suggest strong adoption potential, especially as Yes2Go targets both new users and switches from oral regimens. The company’s target of 75% access within six months and 90% within a year sets an aggressive pace for market penetration.
2. Oncology Pipeline Advances
Trodelvy’s positive phase three results in first-line metastatic triple negative breast cancer expand its addressable market and reinforce Gilead’s oncology ambitions. Trodelvy is already the leading therapy in second-line settings, and first-line approval could double its eligible patient pool and extend duration of therapy. Additional late-stage programs in lung, endometrial, and GI cancers further diversify the pipeline.
3. Cell Therapy and Next-Gen Modalities
Kite’s cell therapy business continues to face competitive headwinds, with sales down 7% year over year, but sequential growth and regulatory changes (e.g., REMS program streamlining) may lower barriers to broader adoption. The upcoming pivotal update from the Imagine I trial in multiple myeloma and next-gen CAR-T constructs could reinvigorate the franchise if efficacy and safety profiles prove differentiated.
4. Global Expansion and Access Partnerships
Gilead’s partnership with the Global Fund to deliver Lenacapavir to two million people in low and middle-income countries signals a strategic push for global HIV prevention leadership. The company is also preparing for European launches, supported by positive CHMP opinions and new WHO guidelines endorsing Lenacapavir.
Key Considerations
Gilead’s Q2 results highlight a company at a strategic pivot, moving from pandemic-driven volatility toward a pipeline-fueled growth trajectory anchored by HIV innovation and oncology expansion. Investors should weigh the durability of HIV franchise growth, the pace of Yes2Go adoption, and the ability to offset headwinds in cell therapy and HCV.
Key Considerations:
- Yes2Go Market Uptake Trajectory: Early access wins and high prescriber awareness are promising, but payer coverage ramp and real-world injection adoption remain critical watchpoints.
- Discovy-to-Yes2Go Patient Migration: As Yes2Go gains traction, expect a shift in mix from oral to injectable PrEP, with Discovy’s growth likely moderating as Yes2Go scales.
- Medicare Part D and Policy Headwinds: Management expects $900 million impact from Medicare redesign on HIV, with further policy shifts (MFN, Medicaid) a source of uncertainty in 2026 and beyond.
- Oncology and Cell Therapy Execution: Trodelvy’s first-line breast cancer filing and Imagine I cell therapy data are pivotal for pipeline-driven upside.
- Cost Structure and Capital Allocation: SG&A and R&D discipline underpin margin resilience, while a new $6 billion buyback authorization signals continued shareholder return focus.
Risks
Policy and reimbursement uncertainty remains a material risk, especially around Medicare and Medicaid changes and potential MFN proposals. Yes2Go’s success depends on rapid payer access and prescriber adoption, with logistical complexity and real-world injection rates still to be proven at scale. Cell therapy faces competitive and regulatory hurdles, while HCV and COVID portfolios are in secular decline. Any delays or setbacks in pipeline milestones could temper the current growth narrative.
Forward Outlook
For Q3 2025, Gilead guided to:
- Base business product sales (ex-Veclury) of $27.3 to $27.7 billion for FY25, up $0.5 billion from prior guidance
- HIV sales growth of approximately 3% for FY25, versus prior flat outlook
For full-year 2025, management raised diluted EPS guidance to $7.95 to $8.25 (up $0.20 at midpoint), and expects operating income of $13 to $13.4 billion. Management cited robust HIV franchise performance, pipeline momentum, and disciplined cost structure as drivers, while maintaining conservative assumptions for new launches and policy impacts.
- Yes2Go launch assumptions unchanged pending access ramp
- Medicare Part D and policy impact assumptions unchanged
Takeaways
Gilead’s Q2 marks a strategic inflection, as HIV innovation and oncology advances offset legacy headwinds. The company is executing on a multi-year transition toward pipeline-driven growth, but access, reimbursement, and market adoption remain key variables.
- Yes2Go Launch is a Defining Catalyst: Early signals are positive, but payer access and prescriber adoption must scale for sustained impact.
- Oncology and Cell Therapy Will Determine Pipeline Upside: Trodelvy’s move into first-line and pivotal cell therapy data are crucial for expanding addressable markets.
- Policy and Mix Shifts Require Ongoing Vigilance: Investors should monitor Medicare/Medicaid headwinds and the evolving HIV product mix as Yes2Go ramps.
Conclusion
Gilead’s Q2 2025 results reflect a company in transformation, with strong execution in HIV and oncology, disciplined cost management, and a high-impact product launch in Yes2Go. The next phase will hinge on market access, international expansion, and pipeline execution to sustain growth beyond legacy product declines.
Industry Read-Through
Gilead’s rapid launch of Yes2Go demonstrates the commercial potential for long-acting injectables in infectious disease prevention, setting a new benchmark for PrEP market expansion. Oncology pipeline momentum highlights the growing importance of ADCs and first-line indications for biopharma portfolios. Policy and payer dynamics remain central for all pharma players, as Medicare and Medicaid reforms increasingly shape revenue trajectories and access strategies. The emphasis on global partnerships and access signals a shift toward broader international market development, especially for high-impact, differentiated therapies.